PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Healing & RecoveryResearch OnlyC
BPC-157 (Oral)
Oral BPC-157
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- C
- Experience
- 99
- Activity
- 45
Overall check-ins
Trackers & reports
Overview
About BPC-157 (Oral)
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- Oral BPC-157
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
157
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
4
Self-reported dose per injection
Median bucket: 0.6–1 mg · Most common: 1–2 mg
Reports span 0.2–2 mg
0.2–0.4 mg
50
0.4–0.6 mg
6
0.6–1 mg
49
1–2 mg
52
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 215 days · Based on 20 repeat reporters
Research
Sources (4)
- Wiki study page →Source
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions
Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018
Tools
Explore more
Explore
More ways to learn about BPC-157 (Oral) from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about BPC-157 (Oral)?
This page summarizes 26 anonymized self-reports from PeptIQ users who track BPC-157 (Oral), including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for BPC-157 (Oral)?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for BPC-157 (Oral)?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is BPC-157 (Oral) safe to use?
This wiki does not assess safety or recommend use. BPC-157 (Oral) is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of BPC-157 (Oral)?
This wiki summarizes observational community reports and linked citations for BPC-157 (Oral). It does not assert therapeutic benefits. See the sources list on this page and the educational profile for BPC-157 (Oral) for study-level context — not medical advice.
What is the legal status of BPC-157 (Oral)?
BPC-157 (Oral) is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of BPC-157 (Oral)?
Safety data quality for BPC-157 (Oral) varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on BPC-157 (Oral)?
This page links 4 sources for BPC-157 (Oral). Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.